Li Jian, Zhou Dao-Bin, Jiao Li, Duan Ming-Hui, Zhang Wei, Zhao Yong-Qiang, Shen Ti
Department of Hematology, PUMC Hospital, CAMS and PUMC, Beijing 100730, China.
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2009 Oct;31(5):567-9.
To evaluate the efficacy and safety of high-dose dexamethasone-based regiments in newly diagnosed multiple myeloma patients with renal impairment.
The clinical data of 22 patients with newly diagnosed multiple myeloma patients with renal impairment who received high-dose dexamethasone-based regiments from August 2006 to August 2008 in Peking Union Medical College Hospital were retrospectively reviewed.
After receiving a median 4 cycles of high-dose dexamethasone-based regiments, renal impairment was reversed in 7 patients (31.8%) with a median time to reversal of 31 days. Sixteen patients (72.7%) achieved overall response, including 7 patients (31.8%) had complete remission / near complete remission. The grade 3 or 4 adverse events included neutropenia (13.6%), infections (22.7%), peripheral neuropathy (9.1%), and ileus (4.5%).
The high-dose dexamethasone-based regiments are safe and effective for newly diagnosed multiple myeloma patients with renal impairment.
评估以大剂量地塞米松为基础的方案对新诊断的合并肾功能损害的多发性骨髓瘤患者的疗效和安全性。
回顾性分析2006年8月至2008年8月在北京协和医院接受以大剂量地塞米松为基础方案治疗的22例新诊断的合并肾功能损害的多发性骨髓瘤患者的临床资料。
接受中位4个周期的以大剂量地塞米松为基础的方案治疗后，7例患者（31.8%）肾功能损害得到逆转，中位逆转时间为31天。16例患者（72.7%）获得总体缓解，其中7例患者（31.8%）达到完全缓解/接近完全缓解。3级或4级不良事件包括中性粒细胞减少（13.6%）、感染（22.7%）、周围神经病变（9.1%）和肠梗阻（4.5%）。
以大剂量地塞米松为基础的方案对新诊断的合并肾功能损害的多发性骨髓瘤患者安全有效。
